Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Recurrence × Memantine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 3 Neoplasm Metastasis 2 Lung Neoplasms 2 Cognitive Dysfunction 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Tobacco Use Disorder 1 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Neurotoxicity Syndromes 1 Melanoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 32 Dexamethasone 30 Rituximab 22 Cytarabine 21 fludarabine phosphate 20 Methotrexate 17 Lenalidomide 17 fludarabine 15 Bortezomib 15 Peripheral Blood Stem Cell Transplantation 14 Calcium Dobesilate 14 Whole-Body Irradiation 13 Mycophenolic Acid 13 Etoposide 13 pembrolizumab 12 Melphalan 12 Filgrastim 12 Paclitaxel 11 Gemcitabine 11 Cyclosporine 11 Carboplatin 11 pomalidomide 10 Busulfan 10 Vincristine 9 carfilzomib 8 Tacrolimus 8 Panobinostat 8 Clofarabine 8 Cetuximab 8 Brentuximab Vedotin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡